Get started
INTELLIA THERAPEUTINTELLIA THERAPEUTINTELLIA THERAPEUT

INTELLIA THERAPEUT

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

38I chart


Full chart

38I upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.27 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.614 CHF
Net income (FY)
‪−405.13 M‬ CHF
Revenue (FY)
‪30.54 M‬ CHF
Shares float
‪100.10 M‬
Beta (1Y)
3.16

Employees


Employees (FY)
526
Change (1Y)
−72 −12.04%
Revenue / Employee (1Y)
‪68.96 K‬ CHF
Net income / Employee (1Y)
‪−914.81 K‬ CHF

About Intellia Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
John M. Leonard
Website
intelliatx.com
Headquarters
Cambridge
Founded
2014
FIGI
BBG00LVDLGQ3
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

38I news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where 38I is featured.

See all sparks 

Frequently Asked Questions


The current price of 38I is 14.394 CHF — it has decreased by −19.01% in the past 24 hours. Watch INTELLIA THERAPEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange INTELLIA THERAPEUT stocks are traded under the ticker 38I.
38I stock has fallen by −19.01% compared to the previous week, the month change is a −19.01% fall, over the last year INTELLIA THERAPEUT has showed a −39.56% decrease.
We've gathered analysts' opinions on INTELLIA THERAPEUT future price: according to them, 38I price has a max estimate of 113.72 CHF and a min estimate of 12.44 CHF. Watch 38I chart and read a more detailed INTELLIA THERAPEUT stock forecast: see what analysts think of INTELLIA THERAPEUT and suggest that you do with its stocks.
38I reached its all-time high on Jul 2, 2021 with the price of 164.330 CHF, and its all-time low was 14.394 CHF and was reached on Nov 14, 2024. View more price dynamics on 38I chart.
See other stocks reaching their highest and lowest prices.
38I stock is 23.48% volatile and has beta coefficient of 3.16. Track INTELLIA THERAPEUT stock price on the chart and check out the list of the most volatile stocks — is INTELLIA THERAPEUT there?
Today INTELLIA THERAPEUT has the market capitalization of ‪1.18 B‬, it has increased by 2.26% over the last week.
Yes, you can track INTELLIA THERAPEUT financials in yearly and quarterly reports right on TradingView.
INTELLIA THERAPEUT is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
38I earnings for the last quarter are −1.14 CHF per share, whereas the estimation was −1.18 CHF resulting in a 3.61% surprise. The estimated earnings for the next quarter are −1.18 CHF per share. See more details about INTELLIA THERAPEUT earnings.
INTELLIA THERAPEUT revenue for the last quarter amounts to ‪7.72 M‬ CHF, despite the estimated figure of ‪7.02 M‬ CHF. In the next quarter, revenue is expected to reach ‪8.21 M‬ CHF.
38I net income for the last quarter is ‪−115.01 M‬ CHF, while the quarter before that showed ‪−132.14 M‬ CHF of net income which accounts for 12.96% change. Track more INTELLIA THERAPEUT financial stats to get the full picture.
No, 38I doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 526.00 employees. See our rating of the largest employees — is INTELLIA THERAPEUT on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTELLIA THERAPEUT EBITDA is ‪−447.04 M‬ CHF, and current EBITDA margin is ‪−1.40 K‬%. See more stats in INTELLIA THERAPEUT financial statements.
Like other stocks, 38I shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTELLIA THERAPEUT stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INTELLIA THERAPEUT technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INTELLIA THERAPEUT stock shows the strong sell signal. See more of INTELLIA THERAPEUT technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.